个人化基因组
PSNL
15.65
-0.28
-1.76%
个人化基因组
US · PSNL
#2890 按市值排名
上市于 2019
15.65
-0.28
-1.76%
实时 - 追踪5344个代码 - 心跳于267秒前
· 2026-10-16 19:30
✦ 量化股权信号 计算方式说明
减持
- 最近一期（2026/Q3）披露持股的机构数量减少了4家。
- 机构持股总比例下降了1.7个百分点。
机构持股
- 机构持股比例
- 80.22% -1.70pp
- 机构数量
- 181 -4
- 数据截至
- 2026/Q3 较上一报告期
持股变动 vs 资金流向
方向一致机构在上一报告期减持了股份，同时该股在最近20个交易日的主力资金呈净流出——两者方向一致。
机构持股变动数据按季度发布且存在滞后；资金流向数据为每日更新。请将其作为方向性的交叉验证参考，而非精确的择时信号。
持股人类型
Mutual Fund42.71%
Public Company16.27%
VC/PE Fund11.88%
Hedge Fund5.83%
Private Company2.33%
Individual/Insider1.21%
Government Pension Fund0.61%
Insurance Company0.54%
Other18.58%
主要股东 截至 2026-07-19
Tempus AI, Inc.
12.21% · 13.04M 股
ARK Investment Management LLC
7.74% · 8.27M 股
BlackRock
6.63% · 7.08M 股
Lightspeed Management Company, LLC
5.71% · 6.10M 股
Columbia Management Investment Advisers, LLC
5.70% · 6.09M 股
Deep Track Capital, LP
3.75% · 4.00M 股
abrdn plc
3.51% · 3.75M 股
Vanguard Capital Management, LLC
3.24% · 3.46M 股
Casdin Capital, LLC
2.39% · 2.55M 股
Kennedy Capital Management LLC
2.21% · 2.36M 股
条形长度是相对于此处列出的最大股东而言，并非相对于公司100%股权。
内部人持股
共追踪50份申报 · 29次买入 · 21次卖出
| 姓名 | 职务 | 持股比例 |
|---|---|---|
| Tempus AI, Inc. | -- | 12.21% |
| Aaron Tachibana | Chief Financial Officer | 0.18% |
| Richard Chen | Executive VP of R&D and Chief Medical Officer | 0.12% |
| Christopher Hall | Chief Executive Officer | 0.09% |
| Stephen Moore | General Counsel | 0.08% |
| Lonnie Shoff | Independent Director | 0.03% |
| Woodrow Myers | Independent Director | 0.02% |
| Olivia Bloom | Independent Director | 0.02% |
| Karin Eastham | Independent Chairperson | 0.01% |
| Arthur Bowman | Independent Director | 0.01% |
内部人交易 最近的 Form 4 申报记录
| 日期 | 姓名 | 职务 | 类型 | 股数 | 价格 |
|---|---|---|---|---|---|
| 2026-09-17 | Richard Chen | Executive VP of R&D and Chief Medical Officer | Open Market Disposition | -3,998 | $16.22 |
| 2026-09-17 | Aaron Tachibana | Chief Financial Officer | Open Market Disposition | -2,931 | $16.22 |
| 2026-09-17 | Stephen Moore | General Counsel | Open Market Disposition | -2,068 | $16.22 |
| 2026-09-17 | Christopher Hall | Chief Executive Officer | Open Market Disposition | -7,459 | $16.22 |
| 2026-07-14 | Richard Chen | Executive VP of R&D and Chief Medical Officer | Derivative Exercise and Sale | -100,000 | $2.44–15.15 |
| 2026-07-08 | Christopher Hall | Chief Executive Officer | Derivative Exercise and Sale | -100,000 | $1.61–15.08 |
| 2026-06-28 | Aaron Tachibana | Chief Financial Officer | Derivative Exercise and Sale | -4,982 | $5.32–14.00 |
| 2026-06-25 | Aaron Tachibana | Chief Financial Officer | Derivative Exercise and Sale | -51,251 | $5.32–13.18 |
| 2026-06-25 | Christopher Hall | Chief Executive Officer | Derivative Exercise and Sale | -100,000 | $1.61–13.15 |
| 2026-06-03 | Aaron Tachibana | Chief Financial Officer | Derivative Exercise and Sale | -40,000 | $9.16–12.01 |
| 2026-05-28 | Aaron Tachibana | Chief Financial Officer | Derivative Exercise and Sale | -38,799 | $9.16–11.58 |
| 2026-05-28 | Christopher Hall | Chief Executive Officer | Derivative Exercise and Sale | -100,000 | $1.61–11.02 |
| 2026-05-27 | Christopher Hall | Chief Executive Officer | Intent to Sell (Form 144) | -100,000 | $9.49 |
| 2026-05-11 | Kenneth Widder | Director | Other Acquisition | +6,250 | -- |
| 2026-05-11 | Kenneth Widder | Director | Other Derivative Acquisition | +37,500 | $6.04 |
| 2026-05-11 | Karin Eastham | Independent Chairperson | Other Acquisition | +6,250 | -- |
| 2026-05-11 | Karin Eastham | Independent Chairperson | Other Derivative Acquisition | +37,500 | $6.04 |
| 2026-05-11 | Arthur Bowman | Independent Director | Other Acquisition | +6,250 | -- |
| 2026-05-11 | Arthur Bowman | Independent Director | Other Derivative Acquisition | +37,500 | $6.04 |
| 2026-05-11 | Woodrow Myers | Independent Director | Other Acquisition | +6,250 | -- |
Form 4 申报记录，每家公司显示最新的一批。"Other Derivative Acquisition"（其他衍生品获取）类目多为限制性股票/期权归属，并非公开市场买入——具体类型见"类型"列。
报价时间 2026-10-16 19:30:05 · 仅供参考，不构成投资建议，也未考虑您的具体情况。
个人化基因组 讨论区 0 条评论